CNN (12/2, LaMotte) reports that cannabis hyperemesis syndrome (CHS) – also known as “scromiting” on social media “due to the combination of screaming and loud vomiting” – is on the “rise in the United States. Habitual users of cannabis, including teenagers, are showing up in emergency rooms complaining of severe intestinal distress.” A studypublished in July “found emergency room visits for adolescents aged 13 to 21 years across the nation increased more than 10-fold between 2016 and 2023,” while a November study“found the rate of CHS among adults 18 to 35 rose sharply during the pandemic years of 2020 and 2021 and remained high.” THC and other cannabinoids in the marijuana plant “have been used for pain relief – paradoxically relieving nausea and vomiting in cancer patients undergoing chemotherapy. However, despite the popularity of marijuana as a [pain reliever], study results on its effectiveness have been mixed.” One possible reason to explain why “the same compound relieve and also cause pain” is “the ever increasing potency of THC in today’s marijuana products.”

Related Links:

— “‘Scromiting,’ a bizarre condition linked to chronic marijuana use, is on the rise,”Sandee LaMotte, CNN, December 2, 2025

The Washington Post (12/2, Sima) reports that researchers earlier this year reported “that the shingles vaccine cuts the risk of developing dementia by 20 percent over a seven-year period.” A large follow-up studypublished Tuesday in Cell “found that shingles vaccination may protect against risks at different stages of dementia – including for people already diagnosed.” The research “found that cognitively healthy people who received the vaccine were less likely to develop mild cognitive impairment, an early symptomatic phase before dementia.” The study suggests that the shingles vaccine “may help people who already have dementia. Those who got the vaccine were almost 30 percent less likely to die of dementia over nine years, suggesting the vaccine may be slowing the progression of the neurodegenerative syndrome.”

Related Links:

— “The Washington Post (requires login and subscription)

HealthDay (12/2, Gotkine) reports a study found that “in early adolescence, smartphone ownership is associated with depression, obesity, and insufficient sleep.” The researchers observed that at age 12 years, “smartphone ownership versus not owning a smartphone was associated with an increased risk for depression, obesity, and insufficient sleep. Associations were seen for younger age of smartphone acquisition with obesity and insufficient sleep. After controlling for baseline mental health and sleep, at age 13 years, among 3,486 youth who did not own a smartphone at age 12 years, those who had acquired a smartphone in the past year had increased odds of reporting clinical-level psychopathology and insufficient sleep when compared with those who had not acquired a smartphone.” The study was published in Pediatrics.

Related Links:

— “Smartphone Ownership Linked To Depression, Obesity, Insufficient Sleep in Early Adolescence, Study Finds,”Elana Gotkine, HealthDay , December 2, 2025

American Journal of Managed Care (11/26, Steinzor) reported a study found that “telehealth has rapidly reshaped outpatient mental health care in the US, with new data showing that nearly 28% of adult mental health outpatients relied exclusively on virtual visits in 2021–2022.” The researchers “analyzed data from the 2021–2022 Medical Expenditure Panel Survey, focusing on 4720 adults aged 18 years or older who reported receiving mental health care.” Among adults surveyed, “27.8% received all telemental health care, 21.5% received hybrid care, and 50.6% received all in-person care.” They observed that “telehealth use was highest among adults aged 18 to 44 years, college graduates, higher-income patients, private insurance holders, and urban residents.” They noted that “psychotherapy users – without medication or with medication – and those with less than moderate distress were also more likely to use telehealth, whereas patients receiving only medication or treated by counselors or social workers.” The study was published in JAMA Psychiatry.

Related Links:

— “Telemental Health Now Serves 1 in 4 Outpatients,”Pearl Steinzor, American Journal of Managed Care , November 26, 2025

HealthDay (11/26, Edwards) reported a study found that many “people who die by suicide without showing prior warning signs, such as suicidal thoughts or past attempts, may have different underlying risk factors than those who express suicidal behavior.” For the study, researchers analyzed “anonymized genetic data from more than 2,700 people who died by suicide.” They found that “about half of people who die by suicide have no known history of suicidal thoughts or behaviors. Many also don’t have diagnosed mental health conditions like depression.” The study “also found that this group wasn’t any more likely than the general population to show traits like chronic low mood or neuroticism. Suicide prevention has long focused on identifying and treating depression and related mental health disorders. But this research suggests that approach may not reach everyone who’s at risk.” The study was published in JAMA Network Open.

Related Links:

— “Some Suicide Victims Show No Typical Warning Signs, Study Finds,”I. Edwards, HealthDay, November 26, 2025

NBC News (11/30, Cox) reports, “Side effects are a key reason people choose to go off their medication, but stopping the drugs can also lead to withdrawal symptoms, research indicates. Along with the growing awareness, a deprescribing movement is building up in the field of psychiatry, aimed at helping patients reduce or stop their medications when no longer considered necessary.” A study published in Psychiatry Research “found that serious withdrawal effects may be more common than previously suspected, especially with longer-term use, although the study was small with just 18% of participants responding to the survey. The results showed that among people who had been taking antidepressants for more than two years, 63% reported moderate or severe withdrawal effects, with a third describing withdrawal issues that lasted more than three months.”

Related Links:

— “Doctors seek to understand why quitting antidepressants causes withdrawal for some,”David Cox, NBC News, November 30, 2025

Healio (11/25, Monostra) reports a study suggests that “women who have thyroid dysfunction both before and during pregnancy may have increased risk for having a child diagnosed with autism spectrum disorder.” Researchers observed that “women who had both chronic and gestational thyroid dysfunction had higher risk for offspring with autism spectrum disorder than women with normal thyroid function. Similarly, women with both chronic and gestational hypothyroidism had increased risk for children with autism spectrum disorder than women with normal thyroid function.” They noted that “each additional trimester of thyroid dysfunction during pregnancy raised the risk for offspring with autism spectrum disorder for women with gestational hypothyroidism only and those with both chronic and gestational hypothyroidism. The risk for having offspring with autism spectrum disorder was highest among women who had gestational hypothyroidism through all three trimesters of pregnancy.” The study was published in The Journal of Clinical Endocrinology & Metabolism.

Related Links:

— “Thyroid dysfunction during pregnancy linked to higher autism risk for offspring,”Michael Monostra, Healio, November 25, 2025

NBC News (11/25, Bush) reports researchers say that for the first time they have “identified four distinct turning points between…phases in an average brain: at ages 9, 32, 66 and 83. During each epoch between those years, our brains show markedly different characteristics in brain architecture, they say.” The study results, “published Tuesday in the journal Nature Communications, suggest that human cognition does not simply increase with age until a peak, then decline. In fact, the phase from ages 9 to 32 is the only time in life when our neural networks are becoming increasingly efficient, according to the research.” They observed that “during the adulthood phase, from 32 to 66, the average person’s brain architecture essentially stabilizes without major changes, at a time when researchers think people are generally plateauing in intelligence and personality. And in the years after the last turning point – 83 and beyond – the brain becomes increasingly reliant on individual regions as connections between them begin to wither away.”

Related Links:

— “Human brains have 5 distinct ‘epochs’ in a lifetime, study finds,”Evan Bush, NBC News, November 25, 2025

The AP (11/25, Ungar) reports researchers estimate that cannabis use disorder “affects about 3 in 10 pot users and can be mild, moderate or severe.” While experts agree that “it’s an addiction – despite the common misconception” that it is not possible with marijuana – few people “who are addicted seek help for it.” A study published in Substance Use & Misuse earlier this year found that “the share of people who got treatment for cannabis use disorder from their nationally representative sample dropped from 19% in 2003 to 13% in 2019.” An earlier study “also found a marked decline and pointed to reasons that include ‘expanding cannabis legalization and more tolerant attitudes.’ Experts said people need to be educated that pot, like alcohol, can be misused and can cause real harm.”

Related Links:

— “More people are addicted to marijuana, but fewer of them are seeking help, experts say,”Laura Ungar , AP , November 25, 2025

MedPage Today (11/24, Rudd) reports, “Human papillomavirus (HPV) vaccination slashed cervical cancer incidence, reduced the risk of precancerous lesions and anogenital warts, and did so without increasing serious side effects, according to two large meta-analyses.” In a “meta-analysis of 225 observational studies with more than 132 million people, females ages 16 years or younger who received HPV vaccines were 80% less likely than their unvaccinated counterparts to develop cervical cancer (RR 0.20, 95% CI 0.09-0.44).” The other meta-analysis, which “included 60 randomized controlled trials (RCTs) with 157,414 participants,” found that “in females ages 15-25 years, vaccination was linked to a 30% reduction in CIN2+ after 6 years regardless of HPV type (RR 0.70, 95% CI 0.56-0.88),” while “CIN2+ risk from vaccine-matched HPV types fell 60% after 6 years (RR 0.40, 95% CI 0.30-0.54).” The findings were published in the Cochrane Database of Systematic Reviews.

Related Links:

— MedPage Today (requires login and subscription)